ATAI Life Sciences NV (9VC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ATAI Life Sciences NV (9VC) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-23.26 Million ≈ $-27.19 Million USD) by net assets (€159.91 Million ≈ $186.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATAI Life Sciences NV (9VC) net asset quality to measure how much of total assets are equity-financed.
ATAI Life Sciences NV - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ATAI Life Sciences NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ATAI Life Sciences NV (9VC) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
ATAI Life Sciences NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
North Long Dragon New Materials Technology Co. Ltd. A
SHE:301357
|
N/A |
|
Aygaz AS
IS:AYGAZ
|
0.003x |
|
Zhuhai Orbita Control Eng
SHE:300053
|
0.013x |
|
Eramet SA
PA:ERA
|
-0.064x |
|
Canfor Corporation
TO:CFP
|
-0.029x |
|
Zensar Technologies Limited
NSE:ZENSARTECH
|
0.134x |
|
EFORT Intelligent Equipment Co Ltd
SHG:688165
|
-0.078x |
|
Guizhou Qianyuan Power Co Ltd
SHE:002039
|
0.125x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences NV (2019–2024)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences NV from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see 9VC market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €116.55 Million ≈ $136.26 Million |
€-82.44 Million ≈ $-96.38 Million |
-0.707x | -105.43% |
| 2023-12-31 | €244.32 Million ≈ $285.63 Million |
€-84.12 Million ≈ $-98.34 Million |
-0.344x | +12.41% |
| 2022-12-31 | €265.77 Million ≈ $310.71 Million |
€-104.47 Million ≈ $-122.13 Million |
-0.393x | -139.88% |
| 2021-12-31 | €385.96 Million ≈ $451.23 Million |
€-63.25 Million ≈ $-73.94 Million |
-0.164x | +24.74% |
| 2020-12-31 | €95.37 Million ≈ $111.50 Million |
€-20.77 Million ≈ $-24.28 Million |
-0.218x | -65.51% |
| 2019-12-31 | €59.64 Million ≈ $69.72 Million |
€-7.85 Million ≈ $-9.17 Million |
-0.132x | -- |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more